An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)First published 20/01/2025 Last updated 20/01/2025 EU PAS number: EUPAS1000000413StudyPlanned